Loading
A trial tests engineered T cells that can target several tumor proteins, including TROP2. Its activity cannot be attributed to TROP2 targeting alone.
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma. ClinicalTrials.gov record last updated 2025-09-03: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2028-01-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/